Dr. Bernard’s interest in the cerebellum is deeply personal. Witnessing her grandfather’s battle with Parkinson’s disease, a debilitating neurodegenerative disorder affecting approximately 90,000 new patients annually in the United States alone, motivated her to investigate the underappreciated functions of this brain region. Parkinson’s disease is characterized by hallmark symptoms such as tremors, rigidity, impaired balance, dementia, and fatigue — all manifestations intimately connected to cerebellar dysfunction and its interaction with broader neural circuits. Her work seeks to delineate how the cerebellum’s neural networks deteriorate in these conditions and how targeted interventions might forestall or mitigate such decline.

At the anatomical level, the cerebellum is positioned at the posterior base of the brain, comprising densely packed neurons that modulate fine motor control and maintain equilibrium. Yet, this structure’s afferent and efferent pathways extend into regions integrating sensory input with higher-order cognitive processing, suggesting that cerebellar health is paramount not only for physical coordination but also for mental acuity. Disruptions to cerebellar neurons—whether through synaptic disconnection, cell death, or loss of interconnectivity—can precipitate widespread dysfunction, impairing an individual’s ability to move seamlessly or think clearly.

Understanding these changes requires sophisticated methodologies. Dr. Bernard and her team utilize behavioral assessments, neuroimaging techniques such as functional MRI and diffusion tensor imaging, and electrophysiological measures to track cerebellar and cortical activity during task performance. By correlating these neurobiological data with clinical assessments of daily living functions, the research elucidates biomarkers of healthy versus pathological aging. The question at the forefront is whether neurostimulation techniques might recalibrate neural rhythms and strengthen connectivity to preserve functional abilities longer into advanced age.

One such neurostimulation method under scrutiny is Theta Burst Stimulation (TBS), a specialized form of transcranial magnetic stimulation (TMS). TBS emits rapid sequences of low-intensity magnetic pulses patterned to align with the brain’s endogenous theta wave frequency (4-8 Hz), which is implicated in learning and memory processes. Unlike conventional TMS, which uses steady-frequency pulses, TBS aims to entrain neural circuits dynamically, potentially inducing long-term potentiation-like effects that enhance synaptic plasticity. Dr. Bernard posits that TBS applied to cerebellar and prefrontal regions might revitalize neural networks responsible for both motor coordination and executive function.

This hypothesis is being rigorously tested in a longitudinal study involving 120 participants stratified into three cohorts: young healthy adults serving as a cognitive baseline, cognitively normal older adults exemplifying typical age-related changes, and older adults with mild cognitive impairment (MCI), a prodromal stage of dementia characterized by measurable cognitive deficits that do not yet severely compromise daily living. The study’s design includes comprehensive cognitive assessments, balance and gait evaluation, and neuroimaging before and after TBS intervention, aimed at discerning the neuromodulatory effects on network connectivity and functional outcomes.

Results from preliminary phases indicate that TBS may bolster participants’ performance in activities of daily living (ADL), such as dressing, mobility, and continence. These findings suggest that enhancing cerebellar-prefrontal circuitry could translate into tangible improvements in autonomy and quality of life. Dr. Bernard emphasizes that while TBS is not a cure and cannot reverse neuronal loss, its capacity to modulate neurophysiological mechanisms associated with memory, attention, and motor control holds promise for delaying the progression of neurodegenerative symptoms.

Beyond aging and neurodegeneration, Dr. Bernard’s research extends to developmental neuroscience, exploring the neurobiological substrates of early parent-infant interactions. Through collaboration with developmental psychologist Dr. Rebecca Brooker and funding from the Mental Research Institute, studies focus on the effects of estrogen fluctuations during pregnancy and postpartum on maternal brain function and infant outcomes. Employing multimodal imaging and hormonal assays, this work investigates how changing neuroendocrine states shape neural pathways linked to maternal responsiveness and child developmental trajectories.

In her role as director of the Lifespan Cognitive and Motor Neuroimaging Laboratory, Dr. Bernard fosters an interdisciplinary research environment combining expertise in statistics, nursing, kinesiology, biology, and clinical medicine. This holistic approach is vital given the brain’s complexity and the multifactorial nature of cognitive and motor disorders. The lab mentors emerging scientists such as Casey Delaney, a neuroscience graduate student contributing to current projects and exemplifying the drive to integrate fundamental neuroscience with translational applications.

This consortium-driven model underscores the necessity of collaborative efforts to tackle the brain’s enigmas. By integrating advanced neuroimaging, neuromodulation techniques, and behavioral science, Dr. Bernard’s work advances a comprehensive framework for understanding how cerebellar circuitry can be harnessed to improve outcomes across the lifespan. Future directions aim to expand TBS applications to more severe and diverse neurodegenerative diseases, potentially offering novel, non-invasive therapeutic avenues.

The implications of this research reverberate beyond academia. As the global population ages, the societal burden of diseases like Parkinson’s and Alzheimer’s escalates, highlighting the urgent need for interventions that maintain independence and cognitive health. Dr. Bernard’s investigations provide a scientific foundation for innovative strategies that transcend symptomatic treatment and target neural network preservation and restoration, fostering the prospect of extended functional longevity.

As we scale new heights in neurotechnology and our grasp of brain dynamics deepens, studies such as these illuminate a path forward—one in which the brain’s hidden potential can be unlocked to mitigate decline and enrich human life. The cerebellum, once relegated to the backstage of neuroscience, now stands front and center, offering promising keys to sustaining memory, movement, and the very essence of who we are.

Subject of Research: Neuroscience; Cerebellar Function; Neurodegenerative Diseases; Cognitive and Motor Interventions

Article Title: Unlocking the Cerebellum: Innovative Neurostimulation Approaches to Preserving Cognition and Movement in Aging

Image Credits: Chris Jarvis/Texas A&M University College of Arts and Sciences

Keywords: Human health, Human biology, Medical specialties, Neurology, Neurological disorders, Neurodegenerative diseases, Alzheimer’s disease, Parkinson’s disease, Cognitive disorders, Dementia

The choroid plexus, a network of specialized epithelial cells located within the brain’s ventricles, is fundamentally responsible for producing cerebrospinal fluid (CSF). In addition to this classical role, the choroid plexus is increasingly recognized as a critical player in maintaining central nervous system homeostasis and mediating neuroimmune interactions. The study underlines a pathological enlargement of the choroid plexus in PD patients, correlating quantitatively with the severity of motor impairments. This finding shifts some focus away from the traditional emphasis on nigrostriatal dopaminergic loss towards considering structural changes in CSF regulation centers.

The glymphatic system, discovered only in the past decade, represents a specialized waste clearance pathway in the brain, facilitating the removal of metabolic byproducts through a network of perivascular channels driven by CSF flow. Dysregulation of this system has been linked to various neurodegenerative diseases, including Alzheimer’s and now, notably, Parkinson’s disease. Liu and colleagues demonstrate that enlargement of the choroid plexus disrupts glymphatic clearance on a regional basis, particularly affecting neural circuits involved in motor control.

Using advanced neuroimaging techniques combined with histopathological analyses, the researchers mapped the correlation between choroid plexus size and glymphatic function in both animal models and human subjects diagnosed with PD. Enlarged choroid plexuses were associated with reduced CSF influx in specific brain regions, notably the basal ganglia and motor cortex, which are integral to movement coordination. This selective impairment provides a mechanistic explanation for the exacerbation of motor symptoms observed clinically.

Furthermore, the study highlights the bidirectional relationship between neuroinflammation and choroid plexus hypertrophy. Chronic inflammatory signaling within the CNS may promote choroid plexus proliferation and dysfunction, thereby compounding glymphatic impairment. This creates a vicious cycle where inflammation and CSF clearance deficits mutually reinforce each other, accelerating neuron loss and symptom progression in Parkinson’s disease.

Intriguingly, the study also explores molecular signatures associated with choroid plexus enlargement. Upregulation of pro-inflammatory cytokines and altered expression of aquaporin-4 channels—key mediators of glymphatic fluid transport—were detected. These molecular alterations suggest potential targets for pharmacological modulation aimed at restoring glymphatic flow and reducing motor deficits.

The clinical implications of these findings are profound. Traditional Parkinson’s treatments largely focus on dopamine replacement strategies, which, while effective for symptom management, do not halt or reverse disease progression. By implicating the choroid plexus and glymphatic system as contributors to motor severity, new therapeutic strategies can be devised to restore proper CSF dynamics and waste clearance, potentially slowing neurodegeneration.

On a methodological level, this research exemplifies the power of integrating multimodal imaging with molecular and functional analyses to unravel complex pathophysiological processes. The team employed dynamic contrast-enhanced MRI to visualize CSF flow in vivo, combined with post-mortem tissue studies, to validate their observations. This comprehensive approach enabled a precise characterization of the spatial and functional disturbances in PD brains.

Moreover, this study challenges the conventional paradigm that predominantly associates motor symptoms in PD with dopaminergic neuron loss. Instead, it introduces a broader perspective where disrupted neurofluid homeostasis and barrier structures contribute substantially to disease manifestations. The authors advocate for the inclusion of glymphatic metrics in future PD diagnostic criteria and disease monitoring protocols.

Beyond Parkinson’s, the findings may have broader relevance to other neurodegenerative disorders where glymphatic dysfunction and choroid plexus alterations may play underrecognized roles. The interconnectedness of neuroimmune signaling, cerebrospinal fluid dynamics, and neuronal health hints at a unified framework for understanding brain aging and pathology.

Importantly, the study encourages the scientific community to investigate how lifestyle and systemic factors influence the choroid plexus and glymphatic function. Sleep, cardiovascular health, and systemic inflammation are known modulators of glymphatic efficiency and may impact PD progression through these newly identified pathways.

Future research directions proposed by Liu et al. include longitudinal studies to track how choroid plexus morphology and glymphatic flow evolve throughout PD progression and in response to therapeutic interventions. Animal models engineered to mimic choroid plexus enlargement may provide vital experimental platforms for testing novel drugs aimed at preserving glymphatic function.

Additionally, this work underscores the potential for biomarker development targeting choroid plexus-derived factors in CSF or blood, which could facilitate early diagnosis or patient stratification based on glymphatic system integrity. Such biomarkers would be invaluable for personalized medicine approaches in Parkinson’s disease.

Given the complexity of the glymphatic system and its nascent field of study, the elucidation of its involvement in PD represents a significant advance. As the brain’s “cleaning” system becomes clearer, so does the opportunity to develop interventions that reduce the buildup of toxic proteins such as alpha-synuclein, which are hallmarks of Parkinson’s pathology.

In conclusion, the study by Liu, Weng, Cai, and colleagues heralds a paradigm shift in understanding Parkinson’s disease motor severity. By unveiling how choroid plexus enlargement disrupts regional glymphatic function, the research paves the way for innovative therapeutic targets aimed at restoring brain fluid homeostasis. This breakthrough reinforces the notion that neurodegeneration is a multi-faceted process, where vascular, immunological, and clearance systems converge to influence disease outcome.

As the field eagerly anticipates follow-up studies, these findings inspire hope that harnessing the glymphatic pathway may one day complement existing treatments, offering improved quality of life for millions affected by Parkinson’s disease worldwide.

Subject of Research: Choroid plexus enlargement and its contribution to motor severity through regional glymphatic dysfunction in Parkinson’s disease.

Article Title: Choroid plexus enlargement contributes to motor severity via regional glymphatic dysfunction in Parkinson’s disease.

Article References:
Liu, L., Weng, Q., Cai, Q. et al. Choroid plexus enlargement contributes to motor severity via regional glymphatic dysfunction in Parkinson’s disease. npj Parkinsons Dis. 11, 134 (2025). https://doi.org/10.1038/s41531-025-00971-8

Image Credits: AI Generated